Phase II, Open, Adaptive, Dose Escalating, Multicentre Titration Study to Assess the Efficacy and Safety of Repeated Subcutaneous Administration of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The percentage of patients with a positive overall satisfactory relief of symptoms on the Likert scale
24 weeks
No
Catherine Lesage, MD
Study Director
Ipsen
Czech Republic: State Institute for Drug Control
8-55-52060-004
NCT01018953
February 2010
January 2011
Name | Location |
---|